Literature DB >> 10619261

CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies.

M Chilosi1, F Adami, M Lestani, L Montagna, L Cimarosto, G Semenzato, G Pizzolo, F Menestrina.   

Abstract

Detection of abnormal numbers and/or distribution of bone marrow (BM) plasma cells (PCs) on trephine biopsies can be important in the differential diagnosis of multiple myeloma (MM) and other PC disorders. A variety of immunohistochemical markers can potentially improve the specificity and sensitivity of PC detection on routine histological sections obtained from trephine BM biopsies, but most of them are not completely satisfactory. In this study, we investigated whether the antibody CD138/B-B4, which is an optimal marker for PC detection on BM aspirates by flow cytometry, can be used successfully for the identification of PCs also on formalin-fixed, decalcified biopsies. A series of samples including normal BM [12], MM [65], monoclonal gammopathies of undetermined significance [44], and B-cell lymphoma of various types [94], including B-cell precursor lymphoblastic leukemia [9], lymphoplasmacytoid [17], immunoblastic [14], lymphocytic/CLL [23], hairy cell leukemia [4], large B-cell [8], mantle-cell [3], marginal zone [6] and follicular [10] lymphomas, have been investigated for CD138 expression using a sensitive immunohistochemical technique. Within the BM microenvironment, CD138 was characterized by excellent sensitivity and specificity. Virtually all normal and neoplastic PCs expressed clear-cut membrane CD138 immunostaining, whereas all other cell types did not. All cases of MM, including plasmablastic and leukemic cases, showed strong immunoreactivity. Conversely, all B-cell lymphomas, including all cases characterized by secretive features, lymphoplasmacytoid, and immunoblastic lymphomas, were completely negative. These results demonstrate that CD138 is a highly sensitive and specific marker that is useful for the rapid and precise localization of normal and neoplastic PCs on routine BM sections. In addition, because of its clear-cut cell membrane localization, CD138 can be used successfully in double-marker immunostaining reactions to evaluate precisely nuclear prognostic markers such as Ki67 and p53 in MMs.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10619261

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  34 in total

Review 1.  Bone marrow immunohistology of plasma cell neoplasms.

Authors:  A Wei; S Juneja
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

2.  CpG DNA activation and plasma-cell differentiation of CD27- naive human B cells.

Authors:  Jennifer Huggins; Tina Pellegrin; Raymond E Felgar; Chungwen Wei; Miguel Brown; Bo Zheng; Eric C B Milner; Steven H Bernstein; Ignacio Sanz; Martin S Zand
Journal:  Blood       Date:  2006-10-10       Impact factor: 22.113

3.  Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry.

Authors:  Samer Z Al-Quran; Lijun Yang; James M Magill; Raul C Braylan; Vonda K Douglas-Nikitin
Journal:  Hum Pathol       Date:  2007-08-21       Impact factor: 3.466

4.  Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin.

Authors:  Martin S Zand; Thuong Vo; Tina Pellegrin; Raymond Felgar; Jane L Liesveld; Jainulabdeen J Ifthikharuddin; Camille N Abboud; Ignacio Sanz; Jennifer Huggins
Journal:  Blood       Date:  2005-12-20       Impact factor: 22.113

5.  Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling.

Authors:  Vernon Wu; Erin Moshier; Siyang Leng; Bart Barlogie; Hearn Jay Cho; Sundar Jagannath; Deepu Madduri; Madhu Mazumdar; Samir Parekh; Ajai Chari
Journal:  Blood Adv       Date:  2018-06-26

Review 6.  Insights into the molecular roles of heparan sulfate proteoglycans (HSPGs-syndecans) in autocrine and paracrine growth factor signaling in the pathogenesis of Hodgkin's lymphoma.

Authors:  Rajendra Gharbaran
Journal:  Tumour Biol       Date:  2016-06-18

Review 7.  Mechanisms of heparanase inhibitors in cancer therapy.

Authors:  Benjamin Heyman; Yiping Yang
Journal:  Exp Hematol       Date:  2016-08-26       Impact factor: 3.084

8.  CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.

Authors:  Eric D Hsi; Roxanne Steinle; Balaji Balasa; Susann Szmania; Aparna Draksharapu; Benny P Shum; Mahrukh Huseni; David Powers; Amulya Nanisetti; Yin Zhang; Audie G Rice; Anne van Abbema; Melanie Wong; Gao Liu; Fenghuang Zhan; Myles Dillon; Shihao Chen; Susan Rhodes; Franklin Fuh; Naoya Tsurushita; Shankar Kumar; Vladimir Vexler; John D Shaughnessy; Bart Barlogie; Frits van Rhee; Mohamad Hussein; Daniel E H Afar; Marna B Williams
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

9.  Combined evaluation of bone marrow aspirate and biopsy is superior in the prognosis of multiple myeloma.

Authors:  Sanja Stifter; Emina Babarović; Toni Valković; Irena Seili-Bekafigo; Christophe Stemberger; Antica Nacinović; Ksenija Lucin; Nives Jonjić
Journal:  Diagn Pathol       Date:  2010-05-18       Impact factor: 2.644

10.  The utility of IgG, IgM, and CD138 immunohistochemistry in the evaluation of autoimmune liver diseases.

Authors:  Kazumichi Abe; Atsushi Takahashi; Yoshihiro Nozawa; Hiromichi Imaizumi; Manabu Hayashi; Ken Okai; Yukiko Kanno; Hiroshi Watanabe; Hiromasa Ohira
Journal:  Med Mol Morphol       Date:  2014-06-27       Impact factor: 2.309

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.